請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21186完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳信銘 | |
| dc.contributor.author | Che-Yu Liu | en |
| dc.contributor.author | 劉哲妤 | zh_TW |
| dc.date.accessioned | 2021-06-08T03:28:20Z | - |
| dc.date.copyright | 2019-08-27 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-23 | |
| dc.identifier.citation | Chen, J.S. and P.N. Sambrook, Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol, 2011. 8(2): p. 81-91.
2. Fleisch, H., J. Maerki, and R. Russell, Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proceedings of the Society for Experimental Biology and Medicine, 1966. 122(2): p. 317-320. 3. Fleisch, H., R.G. Russell, and M.D. Francis, Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science, 1969. 165(3899): p. 1262-4. 4. Gasser, A.B., et al., The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci, 1972. 43(1): p. 31-45. 5. Jung, A., et al., Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. Cancer Res, 1981. 41(8): p. 3233-7. 6. Pollard, M. and P.H. Luckert, Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells. J Natl Cancer Inst, 1985. 75(5): p. 949-54. 7. Fisher, J.E., et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 1999. 96(1): p. 133-138. 8. Passeri, M., et al., Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner, 1991. 15(3): p. 237-47. 9. Paterson, A.H., et al., Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol, 1993. 11(1): p. 59-65. 10. Hughes, D.E., et al., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995. 10(10): p. 1478-87. 11. Sahni, M., et al., Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest, 1993. 91(5): p. 2004-11. 12. Sato, M., et al., Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest, 1991. 88(6): p. 2095-105. 13. Diab, D.L. and N.B. Watts, Denosumab in osteoporosis. Expert Opin Drug Saf, 2014. 13(2): p. 247-53. 14. Cummings, S.R., et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 2009. 361(8): p. 756-65. 15. Papapoulos, S., et al., The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int, 2015. 26(12): p. 2773-83. 16. Ferrari, S., et al., Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int, 2015. 26(12): p. 2763-71. 17. Bedogni, A., et al., Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg, 2010. 68(7): p. 1662-6. 18. Boonen, S., et al., Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med, 2008. 264(4): p. 315-32. 19. Yasuda, H., et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A, 1998. 95(7): p. 3597-602. 20. Kavanagh, K.L., et al., The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A, 2006. 103(20): p. 7829-34. 21. Luckman, S.P., et al., Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res, 1998. 13(4): p. 581-9. 22. Marx, R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg, 2003. 61(9): p. 1115-7. 23. Mariotti, A., Bisphosphonates and osteonecrosis of the jaws. J Dent Educ, 2008. 72(8): p. 919-29. 24. Pickett, F.A. and M. American Academy of Oral, Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines. J Dent Hyg, 2006. 80(3): p. 10. 25. Ruggiero, S.L., et al., American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg, 2014. 72(10): p. 1938-56. 26. Campisi, G., et al., Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol, 2014. 10(2): p. 257-75. 27. Ruggiero, S.L., E.R. Carlson, and L.A. Assael, Comprehensive Review of Bisphosphonate Therapy: Implications for the Oral and Maxillofacial Surgery Patient. Journal of Oral and Maxillofacial Surgery, 2009. 67(5, Supplement): p. 1. 28. Ruggiero, S.L. and B. Mehrotra, Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med, 2009. 60: p. 85-96. 29. Huja, S.S., et al., Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol, 2006. 288(12): p. 1243-9. 30. Ruggiero, S., et al., Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract, 2006. 2(1): p. 7-14. 31. Landesberg, R., et al., Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg, 2008. 66(5): p. 839-47. 32. Rubegni, P. and M. Fimiani, Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med, 2006. 355(22): p. e25. 33. Conte, P. and R. Coleman, Bisphosphonates in the treatment of skeletal metastases. Semin Oncol, 2004. 31(5 Suppl 10): p. 59-63. 34. Albrektsson T, C.B., JacobssonM, and Wennerberg A, Osseointegration of Implants – A Biological and ClinicalOverview. 2017. 35. Albrektsson, T., et al., Osseointegrated Titanium Implants:Requirements for Ensuring a Long-Lasting, Direct Bone-to-Implant Anchorage in Man. Acta Orthopaedica Scandinavica, 2009. 52(2): p. 155-170. 36. Bra-nemark Per-Ingvar; Zarb, G.A.A., Tomas; Rosen, Harvey M. M.D., D.M.D, Tissue-Integrated Prostheses. Osseointegration in Clinical Dentistry. Plastic and Reconstructive Surgery: March 1986 - Volume 77 - Issue 3 - ppg 496-497, 1986. 37. Radiographic parameters for the evaluation of peri-implant tissues. 38. Lavelle, C., D. Wedgwood, and G. Riess, A new implant philosophy. The Journal of Prosthetic Dentistry, 1980. 43(1): p. 71-77. 39. Garg, A.K., Implant Dentistry-E-Book. 2009: Elsevier Health Sciences. 40. Karoussis, I.K., et al., Long-term implant prognosis in patients with and without a history of chronic periodontitis: a 10-year prospective cohort study of the ITI® Dental Implant System. Clinical Oral Implants Research, 2003. 14(3): p. 329-339. 41. van Steenberghe, D., et al., Applicability of osseointegrated oral implants in the rehabilitation of partial edentulism: a prospective multicenter study on 558 fixtures. Int J Oral Maxillofac Implants, 1990. 5(3): p. 272-81. 42. Friberg, B., et al., Mk II: the self-tapping Branemark implant: 5-year results of a prospective 3-center study. Clin Oral Implants Res, 1997. 8(4): p. 279-85. 43. Truhlar, R.S., et al., Distribution of bone quality in patients receiving endosseous dental implants. J Oral Maxillofac Surg, 1997. 55(12 Suppl 5): p. 38-45. 44. Balshi, T.J., et al., Three-year evaluation of Branemark implants connected to angulated abutments. Int J Oral Maxillofac Implants, 1997. 12(1): p. 52-8. 45. Balshi, T.J. and G.J. Wolfinger, Immediate loading of Branemark implants in edentulous mandibles: a preliminary report. Implant Dent, 1997. 6(2): p. 83-8. 46. Weyant, R.J., Characteristics associated with the loss and peri-implant tissue health of endosseous dental implants. Int J Oral Maxillofac Implants, 1994. 9(1): p. 95-102. 47. Preiskel, H.W. and P. Tsolka, Treatment outcomes in implant therapy: the influence of surgical and prosthodontic experience. Int J Prosthodont, 1995. 8(3): p. 273-9. 48. Iyer, S., C. Weiss, and A. Mehta, Effects of drill speed on heat production and the rate and quality of bone formation in dental implant osteotomies. Part II: Relationship between drill speed and healing. Int J Prosthodont, 1997. 10(6): p. 536-40. 49. Eriksson, A.R. and T. Albrektsson, Temperature threshold levels for heat-induced bone tissue injury: a vital-microscopic study in the rabbit. J Prosthet Dent, 1983. 50(1): p. 101-7. 50. Bamias, A., et al., Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 2005. 23(34): p. 8580-7. 51. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. The Journal of the American Dental Association, 2006. 137(8): p. 1144-1150. 52. Lo, J.C., et al., Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. Journal of Oral and Maxillofacial Surgery, 2010. 68(2): p. 243-253. 53. Yuh, D.-Y., et al., The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan. Journal of Dentistry, 2014. 42(10): p. 1343-1352. 54. Rugani, P., et al., Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dent J (Basel), 2016. 4(4). 55. Malden, N. and V. Lopes, An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab, 2012. 30(2): p. 171-82. 56. Chiu, W.Y., et al., The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab, 2014. 99(8): p. 2729-35. 57. Khan, A., et al., Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporosis International, 2016. 27(3): p. 853-859. 58. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. Annals of Internal Medicine, 2009. 151(4): p. 264-269. 59. Ruggiero, S.L., et al., American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery, 2014. 72(10): p. 1938-1956. 60. Fnais, N., et al., Harassment and discrimination in medical training: a systematic review and meta-analysis. Acad Med, 2014. 89(5): p. 817-27. 61. Wells, G., et al., The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Vol. ᅟ. 2000. 62. Duval, S. and R. Tweedie, Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 2000. 56(2): p. 455-63. 63. Borenstein, M., et al., Introduction to meta-analysis. 2011: John Wiley & Sons. 64. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. BMJ, 2003. 327(7414): p. 557-60. 65. Chrcanovic, B., T. Albrektsson, and A. Wennerberg, Bisphosphonates and dental implants: A meta-analysis. Vol. 47. 2016. 66. Ata-Ali, J., et al., What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res, 2016. 27(2): p. e38-46. 67. Chrcanovic, B., N. Lorrayne Costa Leão, and M. Martins, Influence of Different Acid Etchings on the Superficial Characteristics of Ti Sandblasted with Al2O3. Vol. 16. 2013. 1006-1014. 68. Bell, B.M. and R.E. Bell, Oral Bisphosphonates and Dental Implants: A Retrospective Study. Journal of Oral and Maxillofacial Surgery, 2008. 66(5): p. 1022-1024. 69. Jacobsen, C., et al., Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig, 2013. 17(1): p. 167-75. 70. Grant, B.T., et al., Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases. Journal of Oral and Maxillofacial Surgery, 2008. 66(2): p. 223-230. 71. Zahid, T.M., B.Y. Wang, and R.E. Cohen, Influence of bisphosphonates on alveolar bone loss around osseointegrated implants. J Oral Implantol, 2011. 37(3): p. 335-46. 72. Goss, A., et al., The Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Dental Implant Patients: A South Australian Case Series. Journal of Oral and Maxillofacial Surgery, 2010. 68(2): p. 337-343. 73. Serra, M.P.M., C.S. Llorca, and F.J.S. Donat, Oral implants in patients receiving bisphosphonates: A review and update. Medicina Oral, Patologia Oral y Cirugia Bucal, 2008. 13(12): p. E755-E760. 74. Yip, J.K., et al., Association between oral bisphosphonate use and dental implant failure among middle-aged women. Journal of Clinical Periodontology, 2012. 39(4): p. 408-414. 75. Javed, F. and K. Almas, Osseointegration of dental implants in patients undergoing bisphosphonate treatment: A literature review. Journal of Periodontology, 2010. 81(4): p. 479-484. 76. Walter, C., et al., Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent, 2016. 2(1): p. 9. 77. Lazarovici, T.S. and N. Yarom, Risk Factors for Bisphosphonate-Related Osteonecrosis of the Jaws. Journal of Oral and Maxillofacial Surgery, 2011. 69(4): p. 959-960. 78. Marín-Fernández, A.B., et al., Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid. Journal of Clinical and Experimental Dentistry, 2015. 7(3): p. e444-e446. 79. Miniello, T.G., et al., Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant. Braz Dent J, 2015. 26(1): p. 86-8. 80. Holzinger, D., et al., Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 2014. 72(10): p. 1937.e1-1937.e8. 81. Wacholder, S., et al., Selection of controls in case-control studies. I. Principles. Am J Epidemiol, 1992. 135(9): p. 1019-28. 82. Saad, F., et al., Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol, 2015. 68(4): p. 570-7. 83. Tsao, C., et al., Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg, 2013. 71(8): p. 1360-6. 84. Yamazaki, T., et al., Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg, 2012. 41(11): p. 1397-403. 85. Barasch, A., et al., Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res, 2011. 90(4): p. 439-44. 86. Peer, A. and M. Khamaisi, Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res, 2015. 94(2): p. 252-60. 87. Katz, J., et al., Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg, 2011. 40(6): p. 605-11. 88. Nicolatou-Galitis, O., et al., Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2015. 120(6): p. 699-706. 89. Starck, W.J. and B.N. Epker, Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. International Journal of Oral & Maxillofacial Implants, 1995. 10(1). 90. Saad, F., et al., Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol, 2012. 23(5): p. 1341-7. 91. Martin, D.C., et al., Characteristics of Implant Failures in Patients With a History of Oral Bisphosphonate Therapy. Journal of Oral and Maxillofacial Surgery, 2010. 68(3): p. 508-514. 92. Shibli, J., et al., Histological comparison between implants retrieved from patients with and without osteoporosis. International journal of oral and maxillofacial surgery, 2008. 37(4): p. 321-327. 93. Slagter, K.W., G.M. Raghoebar, and A. Vissink, Osteoporosis and edentulous jaws. International Journal of Prosthodontics, 2008. 21(1). 94. Gnant, M., Zoledronic acid in breast cancer: latest findings and interpretations. Therapeutic advances in medical oncology, 2011. 3(6): p. 293-301. 95. Soolari, N. and A. Soolari, Closure of an open wound associated with bisphosphonate-related osteonecrosis of the jaw in a breast cancer patient. Open Dent J, 2011. 5: p. 163-7. 96. Bedogni, A., et al., Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. British Journal of Oral and Maxillofacial Surgery, 2014. 52(7): p. 603-608. 97. Giovannacci, I., et al., Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? J Craniofac Surg, 2016. 27(3): p. 697-701. 98. Kwon, T.G., et al., Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clinical Oral Implants Research, 2014. 25(5): p. 632-640. 99. Barba-Recreo, P., et al., Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats. J Craniomaxillofac Surg, 2014. 42(6): p. 744-50. 100. Jabbour, Z., et al., Bisphosphonates inhibit bone remodeling in the jaw bones of rats and delay healing following tooth extractions. Oral oncology, 2014. 50(5): p. 485-490. 101. Martins, A.S., et al., Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws – A retrospective cohort study. Journal of Cranio-Maxillofacial Surgery, 2017. 45(10): p. 1736-1742. 102. Lopez-Cedrun, J.L., et al., Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series. Br J Oral Maxillofac Surg, 2013. 51(8): p. 874-9. 103. Zushi, Y., et al., Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent, 2017. 3(1): p. 11. 104. Tam, Y., et al., Osteonecrosis of the jaw after implant surgery in patients treated with bisphosphonates--a presentation of six consecutive cases. Clinical implant dentistry and related research, 2014. 16(5): p. 751-761. 105. Kim, J.W., et al., Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw. Clin Oral Investig, 2016. 20(8): p. 2251-2258. 106. Mashiba, T., et al., Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. Journal of Bone and Mineral Research, 2000. 15(4): p. 613-620. 107. Allen, M.R. and D.B. Burr, The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data. Journal of Oral and Maxillofacial Surgery, 2009. 67(5, Supplement): p. 61-70. 108. Taylor, K.H., L.S. Middlefell, and K.D. Mizen, Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg, 2010. 48(3): p. 221-3. 109. Fizazi, K., et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011. 377(9768): p. 813-22. 110. Papapoulos, S., et al., Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res, 2012. 27(3): p. 694-701. 111. Henry, D.H., et al., Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol, 2011. 29(9): p. 1125-32. 112. Jeffcoat, M.K., Safety of oral bisphosphonates: Controlled studies on alveolar bone. International Journal of Oral and Maxillofacial Implants, 2006. 21(3): p. 349-353. 113. Madrid, C. and M. Sanz, What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clinical Oral Implants Research, 2009. 20(SUPPL. 4): p. 87-95. 114. Brooks, J.K., et al., Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 2007. 103(6): p. 780-786. 115. Wang, H.L., D. Weber, and L.K. McCauley, Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. Journal of Periodontology, 2007. 78(3): p. 584-594. 116. Bedogni, A., et al., Oral Bisphosphonate-Associated Osteonecrosis of the Jaw After Implant Surgery: A Case Report and Literature Review. Journal of Oral and Maxillofacial Surgery, 2010. 68(7): p. 1662-1666. 117. Yuan, K., et al., Dental implant failure associated with bacterial infection and long-term bisphosphonate usage: A case report. Implant Dentistry, 2012. 21(1): p. 3-7. 118. Siebert, T., et al., Immediate implant placement in a patient with osteoporosis undergoing Bisphosphonate therapy: 1-Year preliminary prospective study. Journal of Oral Implantology, 2015. 41: p. 360-365. 119. Kasai, T., M.A. Pogrel, and M. Hossaini, The prognosis for dental implants placed in patients taking oral bisphosphonates. Journal of the California Dental Association, 2009. 37(1): p. 39-42. 120. Memon, S., R.L. Weltman, and J.A. Katancik, Oral bisphosphonates: Early endosseous dental implant success and crestal bone changes. a retrospective study. International Journal of Oral and Maxillofacial Implants, 2012. 27(5): p. 1216-1222. 121. Pirih, F.Q., et al., Case report of implant placement in a patient with Paget's disease on bisphosphonate therapy. The Journal of the Michigan Dental Association, 2009. 91(5): p. 38-43. 122. Park, R., et al., Effect of alendronate on bone remodeling around implant in the rat. Journal of Advanced Prosthodontics, 2013. 5(4): p. 374-381. 123. de Oliveira, M.A., et al., The effects of zoledronic acid and dexamethasone on osseointegration of endosseous implants: histological and histomorphometrical evaluation in rats. Clin Oral Implants Res, 2015. 26(4): p. e17-21. 124. Tsetsenekou, E., et al., The influence of alendronate on osseointegration of nanotreated dental implants in New Zealand rabbits. Clinical Oral Implants Research, 2012. 23(6): p. 659-666. 125. S Crawford, B., et al., Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer. Vol. 27. 2009. 984-8. 126. Shirota, T., et al., Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: Report of a case: Case Report. Clinical Oral Implants Research, 2009. 20(12): p. 1402-1408. 127. Ferrari, S., et al., Fibula Free Flap With Endosseous Implants for Reconstructing a Resected Mandible in Bisphosphonate Osteonecrosis. Journal of Oral and Maxillofacial Surgery, 2008. 66(5): p. 999-1003. 128. Kim, J.H., et al., Effect of alendronate on healing of extraction sockets and healing around implants. Oral Diseases, 2011. 17(7): p. 705-711. 129. Albrektsson, T. and A. Wennerberg, Oral implant surfaces: Part 1--review focusing on topographic and chemical properties of different surfaces and in vivo responses to them. Int J Prosthodont, 2004. 17(5): p. 536-43. 130. Chrcanovic, B.R., A.R. Pedrosa, and M.D. Martins, Chemical and topographic analysis of treated surfaces of five different commercial dental titanium implants. Materials Research, 2012. 15: p. 372-382. 131. Ata-Ali, J., F. Ata-Ali, and F. Ata-Ali, Do antibiotics decrease implant failure and postoperative infections? A systematic review and meta-analysis. Int J Oral Maxillofac Surg, 2014. 43(1): p. 68-74. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21186 | - |
| dc.description.abstract | 抑制骨質吸收的藥物(Anit-resorption Agents, ARA)常用於治療骨質疏鬆症或是抑制惡性腫瘤發生骨轉移。今了解,ARA的病患接受牙科手術時,易引起顎骨壞死。然,ARA對牙科植體之影響,學界意見不同。為釐清此爭議,本研究分別以流行病學、統合分析及病例對照研究為方法探討。
流行病學研究方面,調查台大醫院(National Taiwan University Hospital , NTUH)顎骨壞死(medicine related osteonecrosis of jaws, ONJ)的盛行率。比對牙科部之環口全景顎X光片,分析牙科植體與ONJ之關係。結果顯示,ONJ之盛行率為0.24%。比對牙科影像資料,其中兩位ONJ之病因和牙科植體相關。 統合分析研究方面,依據實證醫學的步驟,進行研究。共蒐集1661篇文章,共有11項文獻研究納入統合分析。分析得知,總共7007支植體,其中有1148支植體脫落。微弱證據顯示使用ARA之患者比未使用者具有較高的植體失敗率(OR=1.3),故引用回朔性世代研究調查植體失敗的危險因子。 回朔性世代研究方面,自台大醫院資料庫搜集攝護腺癌、乳癌、多發性骨髓瘤及骨質疏鬆之患者,納入具有植體的患者100名,蒐集其年齡、性別、用藥特性、用藥原因等因子。統計學方面,使用卡方檢定(chi-square),羅吉斯回歸(Logistic regression)等探討牙科植體失敗率及ARA之相關性。結果顯示,使用ARA與否是為影響牙科植體失敗率之關鍵因子,其勝算比為10.47 ( p= 0.00)。多變項迴歸分析顯示下列三項為植體脫落的獨立危險因子: 牙周病與否 (adjusted OR=2.56),使用藥物的原因 (adjusted OR=6.5),使用ARA與否 (adjusted OR=18.4); 使用ARA患者植牙後使用比起植牙前使用有較高失敗率(p=0.04)。女性患者失敗率較高(p=0.01)。有牙周病之患者失敗率較高(p=0.03)。脫落之植體依其形態可分為兩種, 35%為類植體周圍炎樣 (peri-implantitis type),可見齒槽骨由齒槽嵴頂吸收,且呈現類似火山口狀。另外,65%為類骨塊脫離樣 (en-block type),植體仍與骨緊密結合,但有一腐骨中且包含具骨整合植體之病灶產生,與顎骨分離。 藉由本研究,可以見得使用ARA患者其植體成功率為73.6%。女性患有牙周病及在使用抗吸收藥物前已有骨整合之植體,為植體脫落之高危險群。骨塊脫離樣之脫落植體應被定義為真正的植體相關顎骨壞死。綜合以上,牙科植體之手術醫師應謹慎評估當患者曾經使用ARA或是正在使用ARA,仍需注意成功的牙科植體亦可能於患者使用ARA後脫落。此外,基於本研究之限制,仍需要更進一步的前瞻性隨機性研究,方能斷定ARA對牙科植體的影響。 | zh_TW |
| dc.description.abstract | The anti-resorption agents (ARA) can inhibit the osteoclast to reduce bone resorption, which were commonly used in patients with osteoporosis or malignant tumors. To our best knowledge, the alveolar bone surgery induced medicine related osteonecrosis of jaw (ONJ) easily in the patient taking ARA. The prognosis of implants in ARA patients is controversial. In order to investigate this issue, this research was designed as three parts including epidemiology survey, meta-analysis and retrospective study in the relationship of ARA and dental implant prognosis..
Firstly, all the patients under ARA in NTUH were recruited from 2010 to 2016. The study reported the prevalence of ONJ in those patients. The patient with the dental implant who receiving ARA was identified via cross matching the dental panoramic radiograph and the database of prescription. Prevalence of ONJ in NTUH was 0.24%. Two patients had ONJ related to dental implant failure. Secondly, a meta-analysis was conducted to evaluate the impact of the ARA on the dental implantation. In this part, the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement was used. For the meta-analysis, the search resulted in 1661 articles. After selection according to the eligibility criteria, 11 studies were included, with a total of 7007 implants placed, 1148 loss of implants. Patients treated with ARA had more implant failure than those without (OR: 1.3), but the evidence was not strong. There are many of risk factors could not be survey in the meta-analysis, therefor the retrospective study was performed to investigate the risk factors of dental implant failure for patients taking ARA.. Lastly, a retrospective cohort study was performed to identify the key factors, which affected the failure rate of the dental implantation with taking ARA. The patients with osteoporosis or malignant tumors who received dental implants were divided into two groups according to taking ARA or not. The relation of gender, history of systemic disease, age, drug duration, drug types, and primary diseases as risk factors of dental implant failure were reported. For statistics, Chi-square test, logistic regression and odds ratios were calculated for the association of risk factors to ONJ. The study showed that the key factor of implant failure was taking ARA or not (OR= 10.47). The multivariate regression analysis showed that periodontitis condition (OR=2.56), the indication for ARA (OR=6.5), taking the ARA (OR= 18.4) were risk factors of implant loss. The implant failure rate was higher in the patients receiving implantation before anti-resorptive therapy (p=0.04), female patients (p=0.01) and patients with periodontitis (p=0.03). Two patterns of implants loss were noted in this study. Thirty-five percentage of implants loss was “peri-implantitis” type. The marginal ridge resorption was showed on the dental radiography in this type. Another 65% implants loss was “en block” type. A whole bone block with osseointegrated implant was loss like a sequestrum. The retrospective study supported that the successful rate of implant in the patient with ARA was 73.6%. The female patients with osseointegrated implants and periodontitis were high-risk populations of implant loss after anti-resorptive therapy. The implant loss with en block pattern should be defined as real implant-related ONJ. The interests were that the failure of an osseointegrated implant might occur after the anti-resoptive therapies. Further prospective randomized studies with long follow-up period were necessary to identify the influence of ARA on the dental implant failure. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T03:28:20Z (GMT). No. of bitstreams: 1 ntu-108-R03422028-1.pdf: 1606496 bytes, checksum: 60bd3eb4e4e4d3f99ac719c9b4722cfc (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 中文摘要........................................................................................II
Abstract.......................................................................................VI Table of Contents…………………………………………………………………....X Chapter 1 Introduction………………………………..…………………….1 1.1 Anti-resorption agents………………………………………………………1 1.2 Anti-resorption agent and bone remodeling…………………....4 1.3 Osteonecrosis of the jaw…………………………………………………....7 1.3.1 The background of osteonecrosis of the jaw……………………...7 1.3.2 The mechanism of osteonecrosis of the jaw………………………9 1.4 Osseointegration of dental implants …………………………………...11 1.5 Aim of the study………………………………………………………….15 Chapter 2 Epidemiology Survey….....................................16 2.1 Meta-analysis………………………………………………………….....16 2.1.1 Population cohort………………………………………………..16 2.1.2 Case identification……………………………………………….16 2.1.3 Variables and statistical analysis………………………………...16 2.2 Results: Epidemiology of osteonecrosis of the jaw in NTUH……………17 2.2.1 Demographics…………………………………………………....17 2.2.2 Prevalence of osteonecrosis of the jaw (ONJ) in National Taiwan University Hospital…………………………………………………..........18 2.2.3 The risk factors of ONJ in NTUH……………………………..…18 2.2.4 The details of implant in the patient of ONJ in this study…19 2.3 Discussion…………………………………………………………….....20 2.3.1 Epidemiology survey………………………………………….....20 2.3.2 Prevalence of ONJ in NTUH………………………………….....20 2.4 Brief summary of epidemiology survey……………………………24 Chapter 3 Meta-Analysis…………………………………………………..26 3.1 Materials and Methods……………………………………………………26 3.1.1 Search Strategy and Data Sources ……………………………......26 3.1.2 Inclusion criteria……………………………………………….....28 3.1.3 Excluded criteria……………………………………………….....29 3.1.4 Quality Assessment……………………………………………......30 3.1.5 Detecting publication bias………………………………………....31 3.1.6 Data Analysis……………………………………………………...31 3.2 Results…………...……………………………………………………......32 3.2.1 Literature search………………………………………………......32 3.2.2 Participants and studies characteristics……………………....33 3.2.3 Quality assessment of studies…………………………………......34 3.2.4 Publication bias……………………………………………………35 3.2.5 Data analysis………………………………………………………35 3.2.6 The number needed to harm of dental implant failure in the patient under ARA treatment………………………………………………………36 3.3 Discussion……………………………………………………...................36 3.4 Brief of summary…………………………………………………………41 Chapter 4 Retrospective Cohort Study………………………………42 4.1 Subjects and method.………………………………………………….42 4.1.1 Study cohort…………..……………………………………......42 4.1.1.1 Inclusion criteria………………………………………………..42 4.1.1.2 Exclusion criteria……………………………………………….42 4.1.2 Definition of outcome ……..……………………………………...43 4.1.3 Measurement the risk factors of implant failure………….43 4.1.4 Statistical analysis……………………………… …………………44 4.2 Results…………..……………………………………………………...45 4.2.1 Baseline characteristics of study subjects ………….….….……45 4.2.2 Baseline characteristics of ARA and Non-ARA cohorts ……46 4.2.3 The risk factor of implant failure in study subject ..…….…...46 4.2.4 The risk factors of implant failure in different subgroups……...47 4.2.5 The risk factors of implant failure in ARA patients …....…...47 4.2.6 Distribution of study subjects according to the pattern of dental implant loss……………………………………………………….……...48 4.3 Discussion……………...……………………………………………….50 4.3.1 The risk factors in study papulation ……….……………………52 4.3.2 The pattern of implant failure ………….……………………......54 4.3.3 The periodontitis was a risk factor of implant failure in the patient with ARA …………………………………………….………………….56 4.3.4 The osseointegration of dental implant in the patient under anti-resorptive therapies ……………..………………………………......57 4.3.5 The risk factor that might detriment the failure rate of the dental implant but unable the proved in this study……………….58 4.4 Study limitation…………………………………………………….....59 Chapter 5 Conclusions.……………………………………………………........61 Chapter 6 Figures and Tables…………………………………………………63 References……………………………………………………………………………..81 | |
| dc.language.iso | en | |
| dc.subject | 危險因子 | zh_TW |
| dc.subject | 牙科植體 | zh_TW |
| dc.subject | 抑制骨質吸收的藥物 | zh_TW |
| dc.subject | risk factor | en |
| dc.subject | dental implant | en |
| dc.subject | ARA | en |
| dc.subject | Anit-resorption Agents | en |
| dc.title | 抗骨吸收藥物對牙科植體成敗之影響 | zh_TW |
| dc.title | The Effects of Anti-resorption Agents on Dental Implantation | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 郭生興,杜裕康,陳漪紋 | |
| dc.subject.keyword | 抑制骨質吸收的藥物,牙科植體,危險因子, | zh_TW |
| dc.subject.keyword | Anit-resorption Agents, ARA,dental implant,risk factor, | en |
| dc.relation.page | 90 | |
| dc.identifier.doi | 10.6342/NTU201904094 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2019-08-23 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
| 顯示於系所單位: | 臨床牙醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-1.pdf 未授權公開取用 | 1.57 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
